Stock COR CENCORA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Cencora, Inc.

Equities

COR

US03073E1055

Real-time Estimate Cboe BZX
Other stock markets
 03:58:58 2024-04-25 pm EDT 		5-day change 1st Jan Change
240 USD +0.85% Intraday chart for Cencora, Inc. +0.97% +16.66%
Apr. 22 Mizuho Securities Adjusts Price Target on Cencora to $245 From $224 MT
Apr. 17 Cencora Insider Sold Shares Worth $2,553,860, According to a Recent SEC Filing MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.
  • The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

  • The company shows low valuation levels, with an enterprise value at 0.17 times its sales.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • With a 2024 P/E ratio at 22.56 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • The company appears highly valued given the size of its balance sheet.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
CENCORA, INC. Stock Cencora, Inc.
+16.76% 47.42B
B-
ABBOTT LABORATORIES Stock Abbott Laboratories
-3.41% 185B
C+
MEDTRONIC PLC Stock Medtronic plc
-4.32% 107B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.39% 67.55B
A
DEXCOM, INC. Stock DexCom, Inc.
+8.87% 54.6B
B-
HOYA CORPORATION Stock Hoya Corporation
+3.86% 42.24B
B+
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+4.95% 28.24B
A-
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
-0.31% 26.42B
B
TERUMO CORPORATION Stock Terumo Corporation
+12.40% 25.66B
A-
ZIMMER BIOMET HOLDINGS, INC. Stock Zimmer Biomet Holdings, Inc.
-2.30% 24.9B
B
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. COR Stock
  4. Ratings Cencora, Inc.